Lawrence, David S.Tugume, LillianMwandumba, Henry C.Kanyama, CeciliaMuzoora, ConradNuwagira, EdwinNiessen, Louis W.2025-04-032025-04-032022-12-01Lawrence, D. S., Muthoga, C., Meya, D. B., Tugume, L., Williams, D., Rajasingham, R., ... & Kufa, P. (2022). Cost-effectiveness of single, high-dose, liposomal amphotericin regimen for HIV-associated cryptococcal meningitis in five countries in sub-Saharan Africa: an economic analysis of the AMBITION-cm trial. The Lancet Global Health, 10(12), e1845-e1854.1845-e1854https://nru.uncst.go.ug/handle/123456789/10349HIV-associated cryptococcal meningitis is a leading cause of AIDS-related mortality. The AMBITION-cm trial showed that a regimen based on a single high dose of liposomal amphotericin B deoxycholate (AmBisome group) was non-inferior to the WHO-recommended treatment of seven daily doses of amphotericin B deoxycholate (control group) and was associated with fewer adverse events. We present a five-country cost-effectiveness analysis.enArticle